// COMPANY
Latigo Biotherapeutics
MENTIONS 1LAST SEEN AUGUST 3, 2026
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
product·Axios Pro Rata·AUGUST 3, 2026
“Latigo Biotherapeutics, a Thousand Oaks, Calif.-based developer of non-opioid pain management drugs, set IPO terms to 16m shares at $16-$18.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.